Articles tagged with Colorectal Cancer
A new study shows that liquid biopsies can detect lingering disease in patients with oligometastatic colorectal cancer, guiding treatment decisions. The biopsies identify patients who may benefit from immune therapies or targeted treatments based on mutations detected in blood samples.
Researchers found that walnut extracts may create protective proteins and anti-inflammatory actions in the gut to safeguard against H. pylori infection and resulting cancer. The study suggests a promising non-bacterial approach to reduce symptoms of H. pylori infection, warranting further clinical trial investigation.
Researchers sent take-at-home tests to patients overdue for screenings, increasing completion rates by nearly 20% compared to traditional reminders. The intervention cost just $150 per patient, a critical factor for sustainability in community health centers.
A new study found that delaying colonoscopies after abnormal at-home screenings by over 12 months increases the risk of colorectal cancer diagnosis and death. The odds of being diagnosed with late-stage colon cancer increased by approximately 33% at 16 months.
A new study suggests that long-term aspirin use before a diagnosis of colorectal cancer may be associated with lower CRC-specific mortality. Preventing distant metastases leads to fewer deaths from colorectal cancer.
A study of over 200,000 veterans found that delays in colonoscopy after an abnormal stool blood test increase the risk of colorectal cancer and death. Colonoscopy within one year of an abnormal stool test is recommended to prevent polyp progression and stage migration of colorectal cancer.
Researchers at Nagoya University have discovered two types of fibroblasts, meflin and gremlin 1, that play a crucial role in regulating colorectal cancer progression. Altering the balance between these cells could be an effective strategy for preventing cancer progression.
A new technique using deep mutational scanning has identified important mutations in the MSH2 gene associated with Lynch Syndrome, a major cause of hereditary non-polyposis colorectal cancer. This approach could improve predictive value of genetic screening for individuals at risk of developing colorectal cancer.
Research found cancer patients in low-income countries are up to four times more likely to die following surgery, with less post-operative care infrastructure and oncology services. Patients from upper middle-income countries were two times as likely to die compared to high-income countries.
The global demand for cancer surgery is projected to increase by 52% between 2018 and 2040, with the largest relative increase in low-income countries. Improving care systems worldwide is crucial to reduce mortality rates from complications.
African-Americans are more likely to develop cancerous lesions on the right side and suffer from colorectal cancer at a younger age due to unique biological aging patterns. The research found that the right side of the colon in most African-Americans had suffered epigenetic changes contributing to their increased cancer risk.
A recent study found that daily aspirin use does not reduce the risk of colorectal cancer among adults who start taking it after age 70. However, there may be a potential benefit for those who begin taking aspirin at an earlier age.
Researchers developed a simple, affordable test to detect hidden blood in feces, helping identify those at risk of developing colorectal cancer. The test has shown exceptional performance in detecting the disease in patients with low-risk symptoms, reducing the need for unnecessary colonoscopies.
A triple drug combination of irinotecan, cetuximab, and vemurafenib has shown better tumor response rates and longer cancer-free periods compared to a two-drug combination in patients with metastatic colorectal cancer. The treatment targets the BRAF protein directly and blocks cancer growth by targeting epidermal growth factor receptor.
The Stand Up To Cancer initiative will fund a 'Dream Team' of researchers and public awareness campaigns to increase screenings in medically underserved communities. The goal is to develop better approaches to colorectal cancer interception and make the disease preventable with simple tests, while addressing health disparities.
The FDA has approved pembrolizumab, a new immunotherapy drug, as the first-line treatment for patients with advanced colorectal cancer. This approval was made possible by early results from a phase III clinical trial funded by Stand Up To Cancer (SU2C) research.
A new study found that higher BMI is more dangerous for men than women, while a higher waist-to-hip ratio raises colorectal cancer risk in women. Maintaining a healthy weight can reduce the risk of this deadly cancer.
Researchers analyzed SEER 18 data and found adenocarcinomas to be the predominant cancer subtype in screening, surveillance, and prevention. The study also revealed that carcinoid tumors are increasing at a faster rate than adenocarcinomas, but adenocarcinomas are still steadily increasing in most early-onset subgroups.
Researchers discovered that a high proportion of advanced carcinomas carry a mutant form of the Siglec-XII protein, which is rarely expressed in normal humans. This finding may explain why humans are more prone to aggressive cancers compared to chimpanzees.
Residents of Southwest Virginia have set priorities for cancer prevention and early detection, focusing on tobacco cessation, HPV vaccination, lung and colorectal cancer screenings. The region's partnership with the UVA Cancer Center Without Walls aims to improve health outcomes through a collaborative effort.
A new study published in Neurology found that people with multiple sclerosis (MS) had a 72% greater risk of developing bladder cancer compared to those without the disease. However, breast and colorectal cancers did not show a significant association with MS.
A new study published in the Journal of the American College of Surgeons suggests that Medicaid expansion under the Affordable Care Act may lead to earlier diagnoses of colon cancer. Researchers found improved access to care and enhanced surgical care for patients with colon cancer in states that implemented Medicaid expansion.
Researchers have identified specific geographic areas in the US where women diagnosed with early-onset colorectal cancer before age 50 face higher mortality rates. The study found nearly one quarter of adults in hot spot counties reported no physical activity, and fertility may contribute to this variation.
A new predictive model estimates personal risk for advanced polyps and colon cancer in average risk individuals, helping physicians determine screening options. The study identifies lower and higher risk groups among average risk individuals, with approximately 10% deemed high risk for a colonoscopy.
Researchers found that higher-quality diets were associated with improved overall survival among individuals with metastatic colorectal cancer. The study, published in JAMA Network Open, suggests that dietary interventions may be a crucial component of cancer treatment and management.
Researchers at ChristianaCare's Helen F. Graham Cancer Center & Research Institute have identified a link between two crucial signaling pathways in the development and growth of colon cancer. The study found that an imbalance between WNT and RA signaling can lead to the evolution of colorectal cancer from stem cell populations.
The KRYSTAL-1 phase I/II clinical trial has shown that adagrasib can shrink tumours and is well-tolerated by patients with non-small cell lung cancer, colorectal cancer, and other solid tumours. The KRAS G12C mutation affects approximately 14% of lung adenocarcinomas and 4% of colorectal cancers.
Adagrasib achieves objective responses in nearly half of patients with non-small cell lung cancer; encouraging early results are seen in patients with colorectal, pancreatic, and endometrial cancer. The agent targets KRAS G12C mutation, leading to manageable side effects.
A new study found that a faecal immunochemical test (FIT) is almost 100% accurate at ruling out bowel cancer in patients with suspicious symptoms. FIT has been shown to be as sensitive as colonoscopy, the current gold standard for detection of colorectal cancer.
Research reveals thymoquinone's ability to induce apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer, demonstrating its potential as a therapeutic agent. The compound targets CSCs enriched from both sensitive and resistant cell lines, suggesting a promising effect on chemoresistant cells.
The new guideline provides options for different treatments to improve survival rates and quality of life for patients with locally advanced rectal cancer. Recommendations address patient selection, pelvic radiation treatments, integration with chemotherapy and surgery, and follow-up care.
A study of over 600 patients with colorectal cancer found that higher levels of T cells and greater diversity of T cell receptors are associated with better outcomes. The new biomarker, called TCR immuno-sequencing, measures the amount of infiltrated T lymphocytes and their clonality.
Researchers at Sanford Burnham Prebys Medical Discovery Institute have discovered a way to selectively kill aggressive cancer cells by blocking the construction of nuclear pore complexes. This breakthrough could lead to new treatments for deadly tumors such as melanoma, leukemia, and colorectal cancer.
Kanneganti's research focuses on the innate immune system, inflammation, and cell death in health and disease, particularly in colorectal cancer. She aims to understand how innate immune pathways contribute to tumor development and improve cancer treatment strategies.
Researchers discovered that R-spondin treatment reduces intestinal tumor growth and promotes healthy epithelial cell function. The study suggests a new rationale for treating familial adenomatous polyposis patients with APC mutations.
A national survey found that many cancer patients lack nutritional advice and face difficulties such as diarrhoea, appetite loss, and changes in taste and smell. Researchers emphasize the importance of individualized guidance for improved quality of life and overall survival.
A phase 1 clinical trial of sotorasib (AMG 510) demonstrated anti-cancer activity in patients with heavily pretreated advanced solid tumors. Patients with non-small cell lung cancer had a 32% response rate and median progression-free survival of 6.3 months.
A large observational study found that patients who drank two to three cups of coffee per day had longer survival and a lower risk of cancer worsening compared to those who didn't drink coffee. The benefits held for both caffeinated and decaffeinated coffee, but further research is needed to determine the causal connection.
Researchers found that moderate coffee drinkers had a lower risk of death from colorectal cancer compared to non-coffee drinkers. The study suggests that coffee's antioxidant properties may contribute to its potential health benefits for patients with the disease.
A team of scientists has unraveled the molecular basis underlying colorectal cancer by discovering how mutations in RNF43 activate the Wnt signaling pathway. This finding provides potential treatment options for certain types of colorectal cancer.
A study by Florida Atlantic University found that 28.6% of high-risk patients were unaware of the need for repeat colonoscopy or the proper surveillance interval. The researchers emphasize the importance of objective data and clinician sharing findings to improve patient care.
A new study by City of Hope researchers found that Black patients are less likely to receive chemotherapy and have a higher chance of death compared to white patients with advanced colorectal cancer. The study suggests that all patients with liver metastases should be evaluated for surgery, regardless of race.
A new hybrid signature based on DNA mutation and RNA expression patterns has been developed to predict the mutation status and survival of colorectal cancer (CRC) patients. The model achieved high accuracy and was found to be prognostic for CRC patients.
The ESMO Virtual Congress 2020 showcased promising results in triple negative breast cancer, a new class myeloid specific antibody in solid cancer, and health-related quality of life data from a phase 3 immunotherapy study. Keynote lecturers discussed the impact of COVID-19 on patients, oncologists, and healthcare systems.
The BEACON CRC trial demonstrated a survival advantage for patients with chemo-refractory BRAF mutant CRC treated with the combination of BRAF inhibitor encorafenib and EGFR inhibitor cetuximab. PLX8394, a paradox-breaker BRAF inhibitor, showed comparable efficacy to encorafenib in reducing pathway reactivation.
A new study from Lund University found that PDE5 inhibitors can improve prognosis in patients with colorectal cancer. The study revealed a 18% lower risk of death and reduced metastases among men who used the drugs after diagnosis.
A McGill-led study unlocks the behavior of an enzyme involved in cancer cell spread, revealing a delicate interaction between PRL3 and magnesium transport proteins crucial to colorectal cancer growth. This finding calls into question long-standing hypotheses about PRL3's role in cancer spread.
A new model of screening combines better risk assessment, noninvasive testing options, and targeted referrals for colonoscopy to save more lives. The American Gastroenterological Association proposes a universal approach to screening that reaches more people and offers alternatives to colonoscopy.
A novel function of spermine synthase (SMS) has been identified as facilitating colorectal cancer growth, with excessive accumulation of spermidine having harmful effects on cell viability. Combined inhibition of SMS and MYC signaling induces cancer cell death and tumor regression.
A new study published in Epidemiology found that night-time exposure to outdoor artificial light, especially blue light, may increase the risk of colorectal cancer. The research analyzed data from over 2,000 adults and found a 60% higher risk of developing colorectal cancer among those with the highest exposures to blue light.
Researchers found that chronic inflammation alters cell evolution in the colon, leading to a higher mutation rate and increased risk of colorectal cancers. The study also uncovered evidence of positive selection of mutations in genes associated with immune system regulation and cancer susceptibility.
A study found that mailing colorectal cancer screening kits to Medicaid enrollees boosts screening rates by 23.2% and saves costs compared to a reminder-only approach. The mailed kit alternative requires an additional cost of $116 per person screened, but significantly improves screening in low-income populations at a reasonable cost.
A large study found that taking common hypertension medications such as ACE inhibitors and ARBs can lower the risk of developing colorectal cancer. The benefits were seen in patients over 55 and those with a history of colon polyps, but only for the first three years after a negative baseline colonoscopy.
The study reveals that low levels of MBNL1 protein are associated with poor overall survival in various common cancers. Blocking the JNK protein can reverse this mechanism, providing a potential biomarker for selecting patients for treatment. Researchers plan to investigate MBNL1's role in colorectal cancer and explore anti-JNK therapies.
Research uncovering a new mechanism causing colorectal cancer found that abnormal Zeb2 expression undermines the integrity of the intestinal wall, allowing infiltrating bacteria to cause inflammation. Removing the microbiota or modulating the immune system can prevent cancer development.
The Pew Charitable Trusts and Alexander and Margaret Stewart Trust have partnered to support early-career cancer researchers with four-year grants. The five selected scholars will investigate various cancer-related applications, including early detection methods and molecular connections.
A study published in The Lancet found that aspirin reduces colorectal cancer risk by half in genetically predisposed individuals, with preventive efficacy lasting 10-20 years. The CAPP2 trial showed that daily aspirin doses of 600mg reduced cancer risk compared to placebo.
Mutations in TP53 and concomitant mutant p53 proteins in cancer cells have been found to accelerate tumorigenesis and metastasis. The researchers found that the combination of gain of function mutations and loss of heterozygosity provides protection against cell death, promoting a fibrotic microenvironment and inflammation pathways.
A combination of fasting-mimicking diet and vitamin C has been found to delay tumor progression and even cause disease regression in multiple mouse models of colorectal cancer. The treatment works by regulating iron levels and molecular mechanisms involved in oxidative stress, making it a safer alternative to toxic treatments.
Researchers at Indiana University School of Medicine have identified ST2 as a novel checkpoint molecule that could help T cells become more effective in fighting colorectal cancer. By targeting ST2-expressing macrophages, the researchers were able to slow tumor growth and boost T-cell activity.